Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

MYGN
Myriad Genetics Inc
stock NASDAQ

At Close
Jun 2, 2025 3:59:57 PM EDT
4.48USD+6.921%(+0.29)2,909,445
4.47Bid   4.49Ask   0.02Spread
Pre-market
Jun 2, 2025 8:00:30 AM EDT
4.32USD+3.103%(+0.13)1,030
After-hours
Jun 2, 2025 4:00:30 PM EDT
4.46USD-0.446%(-0.02)32,732
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 5, 2022
07:05AM EST  Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the companys strategic transformation and growth plans at the 40th Annual J.P. Morgan Health Care Conference at 2:15 p.m. ET on Jan. 11, 2022.   GlobeNewswire Inc
Jan 4, 2022
04:47PM EST  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished service.   GlobeNewswire Inc
Dec 15, 2021
10:48AM EST  Now is the time when people start to think of new years resolutions to improve their health. For many, the focus is on physical goals like losing weight or exercising more. A nationwide survey suggests that many may want to consider adding mental health resolutions to their list.   GlobeNewswire Inc
07:05AM EST  The New Generation Gap: Nationwide Survey Finds Different   GlobeNewswire Inc
Dec 14, 2021
04:08PM EST  Myriad Genetics Promotes Nicole Lambert To COO   Benzinga
04:05PM EST  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to Paul J. Diaz, president and CEO, Myriad Genetics.   GlobeNewswire Inc
Nov 23, 2021
07:05AM EST  One of the biggest issues parents of teenagers may face is determining if their child is experiencing a mental health challenge or ordinary growing pains.   GlobeNewswire Inc
Nov 22, 2021
07:05AM EST  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment.   GlobeNewswire Inc
Nov 3, 2021
09:11AM EDT  SVB Leerink Maintains Market Perform on Myriad Genetics, Lowers Price Target to $35   Benzinga
Nov 2, 2021
10:58AM EDT  Myriad Genetics Q1 Adj. EPS $(0.02), Inline, Sales $167.30M Beat $165.04M Estimate   Benzinga
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
08:30AM EDT  Myriad Genetics Reports Third Quarter 2021 Results, Continues   GlobeNewswire Inc
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 18, 2021
07:14AM EDT  Myriad Genetics Names Pamela Wong As Chief Legal Officer   RTTNews
Oct 11, 2021
12:01AM EDT  Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they wont seek treatment for mental health conditions and others say they wont get help until these symptoms take a toll in their lives.   GlobeNewswire Inc
Sep 13, 2021
04:05PM EDT  Myriad Genetics Completes Sale of Myriad   GlobeNewswire Inc
Sep 8, 2021
04:05PM EDT  Depression medication trial and error is far too common and may result in additional mental health challenges.   GlobeNewswire Inc
Sep 7, 2021
09:49AM EDT  Illumina Inc. (ILMN) and Merck & Co Inc. (MRK) have partnered to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency or HRD, Illumina said in a statement.   RTTNews
09:27AM EDT  Illumina Partners With Merck To Develop And Commercialize Tests For Use In Identifying Specific Cancer Mutations   RTTNews
09:21AM EDT  Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations   Benzinga
09:16AM EDT  Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic   PR Newswire
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
07:06AM EDT  Myriad Genetics Q4 Adj. EPS $0.12 Beats $(0.07) Estimate, Sales $189.40M Beat $166.73 Estimate   Benzinga
07:05AM EDT  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2021 and provided an update on recent business performance and strategic transformation plans.   GlobeNewswire Inc
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Aug 2, 2021
07:12AM EDT  Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries   Benzinga
07:05AM EDT  -- Myriads MyRisk Hereditary Cancer test with RiskScore provides a breast cancer risk assessment for all women not previously diagnosed with breast cancer, regardless of ancestry -- MyRisk with RiskScore is an important step to help address racial and ethnic disparities in the healthcare system   GlobeNewswire Inc
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 28, 2021
04:05PM EDT  Myriad Genetics to Release Second Quarter Financial   GlobeNewswire Inc
07:05AM EDT  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a recent nationwide poll, the GeneSight Mental Health Monitor.   GlobeNewswire Inc
Jul 21, 2021
04:05PM EDT  Myriad Genetics Supports New ACMG Recommendation Statement on   GlobeNewswire Inc
Jul 13, 2021
10:40AM EDT  Seeing Myriad Genetics Block Trade Of 930K Shares At $33.90/Share   Benzinga
08:05AM EDT  The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data   Benzinga
Jul 1, 2021
04:05PM EDT  Myriad Genetics Completes Sale of Myriad RBM to   GlobeNewswire Inc
Jun 16, 2021
04:16PM EDT  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has named Thomas P. Slavin Jr. (T.J.), M.D., FACMG, DABMD, chief medical officer of the company. He will report directly to Nicole Lambert, president of Myriad Genetic Laboratories.   GlobeNewswire Inc
Jun 15, 2021
10:24AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021   Benzinga
08:19AM EDT  Raymond James Initiates Coverage On Myriad Genetics with Market Perform Rating   Benzinga
Jun 4, 2021
07:05AM EDT  Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the companys transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Global Healthcare Conference at 8:50 a.m. EST on June 10, 2021.   GlobeNewswire Inc
Jun 3, 2021
10:09AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021   Benzinga
06:35AM EDT  Goldman Sachs Initiates Coverage On Myriad Genetics with Sell Rating, Announces Price Target of $25   Benzinga
Jun 1, 2021
07:12AM EDT  Myriad Genetics Completes Sale Of Myriad MyPath Melanoma Laboratory To Castle Biosciences For $32.5 Mln Cash   RTTNews
07:05AM EDT  On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.   GlobeNewswire Inc
May 27, 2021
11:02AM EDT  IPM Launches GeneSight(r) Pharmacogenomics Program for Depression and Anxiety   PR Newswire
May 24, 2021
07:36AM EDT  Genetic testing and precision medicine company Myriad Genetics, Inc. (MYGN) announced Monday it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA Holdings, Inc. (IQV). The terms of the deal were not disclosed.   RTTNews
07:09AM EDT  Myriad Genetics Signs Definitive Agreement To Sell Myriad RBM To Q2 Solutions   RTTNews
07:07AM EDT  Myriad Genetics to Sell its Myriad RBM to Q2 Solutions, Terms Not Disclosed   Benzinga
07:05AM EDT  Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to   GlobeNewswire Inc
May 20, 2021
07:37AM EDT  Myriad Genetics Names Melissa Gonzales President Of Its Women's Health Business   RTTNews
07:05AM EDT  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Melissa Gonzales has been named president of its Womens Health business.   GlobeNewswire Inc
May 19, 2021
05:56PM EDT  Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries   Benzinga
05:55PM EDT  Myriad Genetics to Share New Data at 2021 ASCO Validating   GlobeNewswire Inc
May 5, 2021
04:05PM EDT  Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the companys transformation plan and growth initiatives during a fireside chat at the Bank of America Securities 2021 Virtual Health Care Conference at 2:45 p.m. EDT on May 12, 2021.   GlobeNewswire Inc
May 3, 2021
05:24PM EDT  Myriad Genetics Inc. (MYGN), Monday reported a loss for the first quarter that narrowed from last year and was also lower than Wall Street's expectations, as revenues grew 6% and surpassed estimates.   RTTNews
04:59PM EDT  Recap: Myriad Genetics Q3 Earnings   Benzinga
04:08PM EDT  Myriad Genetics March Quarter GAAP Loss/Shr $0.52 Vs Loss $1.55 Last Year   RTTNews
04:06PM EDT  Myriad Genetics Q3 Adj. EPS $(0.06) Beats $(0.14) Estimate, Sales $173.10M Beat $156.20M Estimate   Benzinga
04:05PM EDT  Myriad Genetics Delivers 12% Sequential Revenue Growth in March   GlobeNewswire Inc
07:26AM EDT  Myriad Genetics, Inc. (MYGN) said the company is focused on returning to long-term organic growth and profitability, and expects to be profitable by fourth quarter of 2021. Beginning the current quarter, Myriad Genetics began to implement the second phase of its transformation plan.   RTTNews
07:21AM EDT  Myriad Genetics, Inc. (MYGN) has agreed to sell select operating assets and intellectual property, including the Vectra test, from Myriad Autoimmune's business unit to Labcorp (LH) for $150 million. Myriad expects the deal to close by the end of the third quarter.   RTTNews
07:17AM EDT  Myriad Genetics Expects To Be Profitable By Q4'21   RTTNews
07:14AM EDT  Myriad Genetics Agrees To Sell Myriad Autoimmune's Vectra Testing Business To Labcorp   RTTNews
07:07AM EDT  Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune's Vectra Testing Business to Labcorp For $150M In Cash   Benzinga
07:05AM EDT  Myriad Genetics Signs Definitive Agreement to Sell Myriad   GlobeNewswire Inc
07:00AM EDT  Labcorp to Acquire Myriad Autoimmune's Vectra Testing Business From Myriad Genetics; Specific Terms Not Disclosed   Benzinga
07:00AM EDT  Myriad Genetics to Update Progress on Transformation Plan and   GlobeNewswire Inc
06:59AM EDT  Labcorp to Acquire Myriad Autoimmune's Vectra Testing Business From Myriad Genetics; No Terms Disclosed   Benzinga
04:13AM EDT  Earnings Scheduled For May 3, 2021   Benzinga
Apr 30, 2021
10:42AM EDT  Myriad Genetics's Earnings Outlook   Benzinga
Apr 28, 2021
07:05AM EDT  In a new nationwide poll, the GeneSight Mental Health Monitor found that 83% of people with depression agree that life would be easier if others could understand their depression. Yet, most people who have not experienced depression may not be able to understand the challenges, including its treatment.   GlobeNewswire Inc
Apr 27, 2021
04:05PM EDT  Myriad Genetics to Release March 2021 Quarterly Financial Results   GlobeNewswire Inc
07:33AM EDT  Myriad Genetics, Inc. (MYGN) has agreed to sell the Myriad myPath Melanoma, LLC, Laboratory, to Castle Biosciences for $32.5 million in cash. myPath Melanoma, LLC, Laboratory is the laboratory that offers the myPath Melanoma test. Myriad expects the transaction to close in its fiscal second quarter.   RTTNews
07:21AM EDT  UPDATE: Myriad Genetics Signs Definitive Agreement To Sell Myriad myPath Melanoma Laboratory To Castle Biosciences For $32.5M In Cash   Benzinga
07:20AM EDT  Castle Biosciences Signs Definitive Agreement To Acquire Myriad myPath Laboratory For $32.5M   Benzinga
07:08AM EDT  Myriad Genetics To Sell Myriad MyPath Melanoma, LLC, Laboratory   RTTNews
07:05AM EDT  Myriad Genetics Signs Definitive Agreement to Sell Myriad   GlobeNewswire Inc
Apr 7, 2021
07:58AM EDT  The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award   Benzinga
Mar 31, 2021
08:00AM EDT  Accomplished technology leader joins Sera to build and deploy its information strategy   GlobeNewswire Inc
Mar 29, 2021
07:05AM EDT  Myriad Genetics Announces Eric Santa as Chief Growth   GlobeNewswire Inc
Mar 17, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
Mar 2, 2021
07:20AM EST  Myriad Genetics Announces Collaboration With Intermountain Precision Genomics For Germline And Somatic Tumor Testing Services Using TheraMap Test And Sequencing Test From Illumina   Benzinga
07:20AM EST  Myriad Genetics Announces Precision Oncology Collaboration With Intermountain Precision Genomics   RTTNews
07:05AM EST  Myriad Genetics Joins Forces with Intermountain Precision Genomics   GlobeNewswire Inc
Feb 26, 2021
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 24, 2021
05:20AM EST  SVB Leerink Maintains Market Perform on Myriad Genetics, Raises Price Target to $33   Benzinga
Feb 23, 2021
05:10PM EST  Recap: Myriad Genetics Q2 Earnings   Benzinga
04:10PM EST  Myriad Genetics Q2 Adj. EPS $(0.12), Inline, Sales $154.60M Beat $150.39M Estimate   Benzinga
04:09PM EST  Myriad Genetics Q4 GAAP Loss/Shr $0.59 And Adjusted Loss/Shr $0.12   RTTNews
04:05PM EST  Myriad Genetics Delivers 6% Sequential Revenue   GlobeNewswire Inc
07:25AM EST  The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts   Benzinga
04:09AM EST  Earnings Scheduled For February 23, 2021   Benzinga
Feb 22, 2021
10:14AM EST  A Preview Of Myriad Genetics's Earnings   Benzinga
Feb 18, 2021
04:12PM EST  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new technology and healthcare leaders who recently joined the company as well as key promotions to drive critical business functions, transformation and growth initiatives.   GlobeNewswire Inc
Feb 16, 2021
04:05PM EST  Myriad Genetics to Announce December 2020 Quarterly Financial   GlobeNewswire Inc
Feb 12, 2021
07:07AM EST  Myriad Genetics Says New Study From University Of Utah Radiation Oncologist Ability Of Co's Genetics' Prolaris Test To Guide Treatment For Prostate Cancer   Benzinga
07:05AM EST  New Study from Leading University of Utah Radiation Oncologist   GlobeNewswire Inc
Feb 11, 2021
04:05PM EST  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming health and technology conferences, sharing insights on how the company is intensifying its focus on serving patients and healthcare providers in Womens Health, Oncology and Mental Health.   GlobeNewswire Inc
Feb 8, 2021
07:05AM EST  GeneSight Psychotropic Tests Combinatorial   GlobeNewswire Inc
Feb 4, 2021
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
Feb 2, 2021
07:09AM EST  Myriad Genetics Reports Launch Of New Vectra Cardivascular Risk Assessment For Patients With Rheumatoid Arthritis   Benzinga
07:05AM EST  Myriad Genetics Launches New Vectra Cardiovascular   GlobeNewswire Inc
Jan 19, 2021
07:16AM EST  Myriad Genetics Gets Reimbursement For BRACAnalysis Diagnostic System In Japan   RTTNews
07:14AM EST  Myriad Genetics Receives Reimbursement For BRACAnalysis Diagnostic System In Japan   Benzinga
Jan 18, 2021
08:45AM EST  Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors   PR Newswire
Jan 11, 2021
02:08PM EST  Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling   Benzinga
02:06PM EST  Myriad Genetics Forms Strategic Partnership with Illumina in Oncology For Illumina To Create A Kit-based Version Of The MyChoice Companion Diagnostic Test For International Markets   Benzinga
02:05PM EST  Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following direct link or through the investor section of Myriads website at www.myriad.com.   GlobeNewswire Inc
Jan 8, 2021
07:16AM EST  Myriad Genetics, Inc. (MYGN) said it received first reimbursement decision for the myChoice Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula. myChoice was approved by Japan's Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication.   RTTNews
07:09AM EST  Myriad Genetics Receives First Reimbursement Decision For Myriad MyChoice Diagnostic System   RTTNews
Jan 6, 2021
07:31AM EST  The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping   Benzinga
Jan 5, 2021
04:09PM EST  Myriad Genetics To Restructuring Its Int'l. Operations To Focus On Direct Selling Efforts In Germany, France, Japan   Benzinga
04:08PM EST  Myriad Genetics Reports Q2 Sales For Its BRACAnalysis CDx Test Volume In Japan Up 200% Year Over Year To $7.5M   Benzinga
04:06PM EST  UPDATE: Myriad Genetics Says Will Focus On Women's Health, Oncology, Mental Health   Benzinga
04:05PM EST  Myriad Genetics Reports Will Pursue Strategic Alternatives For Its Autoimmune Business   Benzinga
04:05PM EST  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic business unit and products review which will enable the company to better serve patients and healthcare providers and further expand its leadership in Womens Health, Oncology and Mental Health.   GlobeNewswire Inc
Jan 4, 2021
07:05AM EST  Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the companys transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference at 2:50 p.m. EST on January 11, 2021.   GlobeNewswire Inc
Dec 11, 2020
07:07AM EST  Myriad Genetics Highlights Presentation Of Its myRisk Hereditary Cancer And riskScore Tests At 2020 San Antonio Breast Cancer Symposium   Benzinga
07:05AM EST  New Study Provides Personalized Breast Cancer Risk Information for   GlobeNewswire Inc
Nov 30, 2020
11:01AM EST  Integrated Prescription Mgmt. Reports Signed Contract With Myriad Genetics For Launch Of Personalized Multibiomarker Program For People With Rheumatoid Arthritis   Benzinga
11:00AM EST  IPM Launches Innovative Program for Rheumatoid Arthritis   PR Newswire
Nov 17, 2020
07:05AM EST  A new nationwide poll, the GeneSight Mental Health Monitor, shows that nearly two-thirds (61%) of Americans age 65 or older who have concerns about having depression will not seek treatment. In fact, nearly 1 in 3 (33%) seniors who are concerned they might be suffering from depression believe they can snap out of it on their own. GeneSight is a product of Myriad Genetics, Inc.   GlobeNewswire Inc
Nov 16, 2020
07:05AM EST  Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice tumor testing in several European markets and China.   GlobeNewswire Inc
05:49AM EST  Burning Rock Announced In-Licensing of Myriad myChoice Tumor Testing in China   Benzinga
Nov 15, 2020
08:00PM EST  Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock) today announced that it entered into a development and commercialization agreement with Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad) which will bring myChoice tumor testing for homologous recombination deficiency, or HRD, to China.   GlobeNewswire Inc
Nov 11, 2020
07:06AM EST  Myriad Highlights Presentation Of Data At American College Of Rheumatology   Benzinga
07:05AM EST  New Data Show Importance of Vectra Testing and   GlobeNewswire Inc
Nov 9, 2020
08:10AM EST  Myriad Genetics Q1 Adj. EPS $(0.15) Beats $(0.30) Estimate, Sales $145.20M Down From $186.30M YoY   Benzinga
08:00AM EST  Myriad Genetics Delivers 56% Sequential Increase in Quarterly   GlobeNewswire Inc
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 4, 2020
07:05AM EST  Myriad Genetics to Announce Quarterly Financial Results on   GlobeNewswire Inc
Oct 15, 2020
07:12AM EDT  Myriad Genetics Inc Will Adjust Fiscal Year End From June 30 To Dec 31   Benzinga
07:05AM EDT  Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the company has filed its fiscal year 2020 proxy statement and made significant changes to its board structure, executive compensation and corporate governance policies to better serve key company stakeholders.   GlobeNewswire Inc
Sep 16, 2020
10:58AM EDT  Insider Sells Myriad Genetics Stock   Benzinga
Sep 10, 2020
09:37AM EDT  Myriad Genetics Adds Rashmi Kumar To Board   RTTNews
Aug 21, 2020
07:05AM EDT  American Society of Clinical Oncology Exclusively Cites   GlobeNewswire Inc
Aug 14, 2020
04:05PM EDT  Myriad Genetics Announces Inducement Awards   GlobeNewswire Inc
08:26AM EDT  The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal   Benzinga
Aug 13, 2020
04:28PM EDT  Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors   Benzinga
04:23PM EDT  Myriad Genetics Q4 Loss/share $0.74 Vs. Loss $0.06 Year Ago   RTTNews
04:19PM EDT  Recap: Myriad Genetics Q4 Earnings   Benzinga
04:09PM EDT  Myriad Genetics Q4 Adj. EPS $(0.31) Beats $(0.47) Estimate, Sales $93.20M Miss $93.85M Estimate   Benzinga
04:08PM EDT  Myriad Genetics Appoints Paul J. Diaz as President and Chief   GlobeNewswire Inc
04:07PM EDT  -- Test Volumes Improved Meaningfully By the End of the Fourth Quarter Following Substantial Declines in March and April Due to the Initiation of Social Distancing Policies -- Total Fourth-Quarter Revenues of $93.2 Million -- Fourth-Quarter Diluted EPS of ($0.74) and Adjusted EPS of ($0.31)   GlobeNewswire Inc
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Aug 12, 2020
11:02AM EDT  Preview: Myriad Genetics's Earnings   Benzinga
Aug 10, 2020
07:53AM EDT  Myriad Genetics Announces New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions   Benzinga
07:05AM EDT  New Study Shows Screening Based on Self-Reported Ethnicity Fails   GlobeNewswire Inc
Aug 6, 2020
07:05AM EDT  Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020   GlobeNewswire Inc
Jul 31, 2020
07:05AM EDT  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis CDx for men with prostate cancer who are eligible or may become eligible for treatment Lynparza (olaparib). BRACAnalysis CDx is the only germline test covered for this indication.   GlobeNewswire Inc
Jul 29, 2020
07:21AM EDT  Myriad Launches Proprietary AMPLIFY Technology, Further Increasing The Performance Of Its Prequel NIPS Test   Benzinga
07:05AM EDT  Myriad Launches Proprietary AMPLIFY Technology,   GlobeNewswire Inc
Jul 28, 2020
07:09AM EDT  Myriad Announces Launch Of New Radiographic Progression Prognostic Tool, Adding To Clinical Value Of Vectra   Benzinga
07:05AM EDT  Myriad Announces the Launch of a New Radiographic Progression   GlobeNewswire Inc
Jul 22, 2020
07:23AM EDT  Myriad Genetics Adds Daniel Skovronsky To Board; Walter Gilbert To Retire From Board   RTTNews
07:05AM EDT  Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriads Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC